196 related articles for article (PubMed ID: 32630674)
1. The Specific IKKε/TBK1 Inhibitor Amlexanox Suppresses Human Melanoma by the Inhibition of Autophagy, NF-κB and MAP Kinase Pathways.
Möller M; Wasel J; Schmetzer J; Weiß U; Meissner M; Schiffmann S; Weigert A; Möser CV; Niederberger E
Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32630674
[TBL] [Abstract][Full Text] [Related]
2. Dual TBK1/IKKε inhibitor amlexanox mitigates palmitic acid-induced hepatotoxicity and lipoapoptosis in vitro.
Zhou Z; Qi J; Lim CW; Kim JW; Kim B
Toxicology; 2020 Nov; 444():152579. PubMed ID: 32905826
[TBL] [Abstract][Full Text] [Related]
3. The protein kinase IKKepsilon contributes to tumour growth and tumour pain in a melanoma model.
Möser CV; Meissner M; Laarmann K; Olbrich K; King-Himmelreich TS; Wolters MC; Geisslinger G; Niederberger E
Biochem Pharmacol; 2016 Mar; 103():64-73. PubMed ID: 26793999
[TBL] [Abstract][Full Text] [Related]
4. Aphthous ulcer drug inhibits prostate tumor metastasis by targeting IKKɛ/TBK1/NF-κB signaling.
Cheng C; Ji Z; Sheng Y; Wang J; Sun Y; Zhao H; Li X; Wang X; He Y; Yao J; Wang L; Zhang C; Guo Y; Zhang J; Gao WQ; Zhu HH
Theranostics; 2018; 8(17):4633-4648. PubMed ID: 30279728
[TBL] [Abstract][Full Text] [Related]
5. Dual TBK1/IKKɛ inhibitor amlexanox attenuates the severity of hepatotoxin-induced liver fibrosis and biliary fibrosis in mice.
Zhou Z; Qi J; Zhao J; Lim CW; Kim JW; Kim B
J Cell Mol Med; 2020 Jan; 24(2):1383-1398. PubMed ID: 31821710
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological activity of substituted 2-amino-5-oxo-5H-chromeno[2,3-b]pyridine-3-carboxylic acid derivatives as inhibitors of the inflammatory kinases TBK1 and IKKε for the treatment of obesity.
Beyett TS; Gan X; Reilly SM; Gomez AV; Chang L; Tesmer JJG; Saltiel AR; Showalter HD
Bioorg Med Chem; 2018 Nov; 26(20):5443-5461. PubMed ID: 30270002
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological inhibition of the IKKε/TBK-1 axis potentiates the anti-tumour and anti-metastatic effects of Docetaxel in mouse models of breast cancer.
Bishop RT; Marino S; de Ridder D; Allen RJ; Lefley DV; Sims AH; Wang N; Ottewell PD; Idris AI
Cancer Lett; 2019 May; 450():76-87. PubMed ID: 30790681
[TBL] [Abstract][Full Text] [Related]
8. Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation.
Clark K; Plater L; Peggie M; Cohen P
J Biol Chem; 2009 May; 284(21):14136-46. PubMed ID: 19307177
[TBL] [Abstract][Full Text] [Related]
9. Amlexanox ameliorates acetaminophen-induced acute liver injury by reducing oxidative stress in mice.
Qi J; Zhou Z; Lim CW; Kim JW; Kim B
Toxicol Appl Pharmacol; 2019 Dec; 385():114767. PubMed ID: 31697998
[TBL] [Abstract][Full Text] [Related]
10. Carboxylic Acid Derivatives of Amlexanox Display Enhanced Potency toward TBK1 and IKK
Beyett TS; Gan X; Reilly SM; Chang L; Gomez AV; Saltiel AR; Showalter HD; Tesmer JJG
Mol Pharmacol; 2018 Oct; 94(4):1210-1219. PubMed ID: 30082428
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the protein kinase IKKepsilon attenuates neuropathic pain in mice.
Möser CV; Möller M; Fleck SC; Thomas D; Geisslinger G; Niederberger E
Neuropharmacology; 2019 Mar; 146():198-211. PubMed ID: 30528326
[TBL] [Abstract][Full Text] [Related]
12. IKKε and TBK1 in diffuse large B-cell lymphoma: A possible mechanism of action of an IKKε/TBK1 inhibitor to repress NF-κB and IL-10 signalling.
Carr M; Mamand S; Chapman KL; Perrior T; Wagner SD
J Cell Mol Med; 2020 Oct; 24(19):11573-11582. PubMed ID: 32858764
[TBL] [Abstract][Full Text] [Related]
13. Amlexanox reversed non-alcoholic fatty liver disease through IKKε inhibition of hepatic stellate cell.
He Q; Xia X; Yao K; Zeng J; Wang W; Wu Q; Tang R; Zou X
Life Sci; 2019 Dec; 239():117010. PubMed ID: 31672578
[TBL] [Abstract][Full Text] [Related]
14. Long-term subcutaneous injection of lipopolysaccharides and high-fat diet induced non-alcoholic fatty liver disease through IKKε/ NF-κB signaling.
He Q; Zeng J; Yao K; Wang W; Wu Q; Tang R; Xia X; Zou X
Biochem Biophys Res Commun; 2020 Nov; 532(3):362-369. PubMed ID: 32883523
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of TBK1 by amlexanox attenuates paraquat-induced acute lung injury.
Wang N; Li Y; Wang X; Ma Z; Wang Y; Zhang C; Yuan Y; Zhao M
Toxicology; 2020 Oct; 443():152555. PubMed ID: 32763286
[TBL] [Abstract][Full Text] [Related]
16. Identification of TBK1 and IKKε, the non-canonical IκB kinases, as crucial pro-survival factors in HTLV-1-transformed T lymphocytes.
Zhang H; Chen L; Cai SH; Cheng H
Leuk Res; 2016 Jul; 46():37-44. PubMed ID: 27123832
[TBL] [Abstract][Full Text] [Related]
17. Amlexanox, a selective inhibitor of IKBKE, generates anti-tumoral effects by disrupting the Hippo pathway in human glioblastoma cell lines.
Liu Y; Lu J; Zhang Z; Zhu L; Dong S; Guo G; Li R; Nan Y; Yu K; Zhong Y; Huang Q
Cell Death Dis; 2017 Aug; 8(8):e3022. PubMed ID: 29048430
[TBL] [Abstract][Full Text] [Related]
18. Amlexanox attenuates LPS-induced neuroinflammatory responses in microglial cells via inhibition of NF-κB and STAT3 signaling pathways.
Phan Van T; Huyen Ton Nu Bao T; Leya M; Zhou Z; Jeong H; Lim CW; Kim B
Sci Rep; 2024 Feb; 14(1):2744. PubMed ID: 38302598
[TBL] [Abstract][Full Text] [Related]
19. TANK-binding kinase 1 (TBK1) modulates inflammatory hyperalgesia by regulating MAP kinases and NF-κB dependent genes.
Möser CV; Stephan H; Altenrath K; Kynast KL; Russe OQ; Olbrich K; Geisslinger G; Niederberger E
J Neuroinflammation; 2015 May; 12():100. PubMed ID: 25997745
[TBL] [Abstract][Full Text] [Related]
20. TBK1 and IKKε Act Redundantly to Mediate STING-Induced NF-κB Responses in Myeloid Cells.
Balka KR; Louis C; Saunders TL; Smith AM; Calleja DJ; D'Silva DB; Moghaddas F; Tailler M; Lawlor KE; Zhan Y; Burns CJ; Wicks IP; Miner JJ; Kile BT; Masters SL; De Nardo D
Cell Rep; 2020 Apr; 31(1):107492. PubMed ID: 32268090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
